ClinicalTrialsFinder
RecruitingNCT05567133

Risk Indicators of Sarcoidosis Evolution-Unified Protocol

Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis

Sponsor

University of California, San Francisco

Enrollment

200 participants

Start Date

Jan 10, 2023

Study Type

OBSERVATIONAL

Conditions

Sarcoidosis, Pulmonary

Summary

The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with sarcoidosis, pulmonary. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(2)

University of Maryland

Baltimore, Maryland, United States

UT Southwestern

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05567133

Related Trials

Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis

NCT0584175821 locations

Feasibility of Semaglutide in Advanced Lung Disease

NCT057460391 location

Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy

NCT053744471 location

RCT of Nintedanib in Fibrotic Sarcoidosis

NCT064796031 location

Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease

NCT034556861 location